Skip to main content
. 2018 Mar 15;197(6):776–787. doi: 10.1164/rccm.201707-1371OC

Figure 3.

Figure 3.

Cardiopulmonary effects of prenatal maternal uterine artery anti–sFlt-1 (soluble fms-like tyrosine kinase 1) monoclonal antibody (mAb) injection in experimental preeclampsia. (A) As shown, distal lung growth is enhanced by maternal mAb infusion after intraamniotic (i.a.) sFlt-1 exposure. In comparison with control (CTL), radial alveolar counts are decreased after i.a. sFlt-1 exposure and are restored after maternal uterine artery mAb infusion. Scale bars, 100 μm. (B) Similarly, lung vessel density is reduced after i.a. sFlt-1 exposure but is enhanced after prenatal maternal uterine artery mAb treatment. Scale bars, 250 μm. (C) In addition, uterine artery infusion of mAb improved the development of right ventricular hypertrophy after sFlt-1 exposure in utero. As shown, uterine artery injection with nonspecific IgG did not affect radial alveolar counts (A), vessel density (B), or right ventricular hypertrophy (C) in saline control rats and did not alter the adverse effects of i.a. sFlt-1. Error bars show SEM. Numbers of pups studied in each group are: CTL, n = 32; sFlt-1, n = 23; mAb alone, n = 10; sFlt-1 + mAb (1 mg/kg), n = 19; sFlt-1 + mAb (10 mg/kg), maternal IgG, n = 15; sFlt-1 + IgG, n = 12. HPF = high-power field; LV = left ventricle; RV = right ventricle; S = septum.